A new combination therapy has been found to give better results for patients with a certain type of colorectal cancer that no ...

Patients with previously treated non-small cell lung cancer (NSCLC) whose tumors harbored a KRAS G12D mutation experienced ...

A novel combination therapy offers better outcomes for patients with KRAS G12C metastatic colorectal cancer that have stopped ...

Doctors and scientists at MSK are leaders in the study of the KRAS family of genes. Two drugs that block the KRAS-G12C subtype have received approvals from the U.S. Food and Drug Administration (FDA) ...

A novel combination therapy offers better outcomes for patients with KRAS G12C metastatic colorectal cancer that have stopped responding to chemotherapy, according to a Phase 3 clinical trial by ...

A new drug combination shows promise for colon cancer patients whose disease no longer responds to standard chemotherapy ...

KRAS G12C inhibitors mark a breakthrough in oncology, but resistance is driving the need for smarter preclinical models and ...

Small molecule + anti-PD-1 combo therapy will unlock new first-line opportunity in the KRAS G12C segment. 7.1. HER2 and NRG1+ segments are evolving NSCLC segments while BRAF and METex14 skipping ...

A novel combination therapy offers better outcomes for patients with KRAS G12C metastatic colorectal cancer that have stopped ...